DelveInsight’s “Eye Neoplasms Market Insights, Epidemiology, and Market Forecast-2032“ report delivers an in-depth understanding of the Eye Neoplasms, epidemiology insights, Eye Neoplasms market trends, therapies, and key companies working in the Eye Neoplasms Market in the 7MM.
Eye Neoplasms Overview
Eye neoplasms can affect all parts of the eye, and can be a benign tumor or a malignant tumor (cancer). Eye cancers can be primary (starts within the eye) or metastatic cancer (spread to the eye from another organ). The two most common cancers that spread to the eye from another organ are breast cancer and lung cancer. Other less common sites of origin include the prostate, kidney, thyroid, skin, colon, and blood or bone marrow. The most common benign tumor in the eye is a choroidal nevus. Another eye tumor is a choroidal hemangioma, which is a vascular tumor. Although many of these benign tumors do not cause vision loss, if it is located in the macula — the central retina that provides detailed vision — patients can experience vision changes.
Eye Neoplasms Epidemiology Insights
-
The average annual incidence rate (new cases) in the U.S. is about 1/100,000 population and the estimated prevalence rate (total cases) is about 12/100,000 population.
-
With few exceptions, eye cancer occurs more frequently in whites than in blacks and more often in older than in younger people.
-
The survival rate for persons with localized ocular tumors receiving early treatment is almost 80%.
Click here to learn more about the Eye Neoplasms Market Landscape
The Report Covers the Eye Neoplasms Epidemiology Segmented by:
-
Total Eye Neoplasms incident cases
-
Total Eye Neoplasms prevalent cases
-
Total Eye Neoplasms treatment cases
-
Total Eye Neoplasm diagnostic cases
Eye Neoplasms Market Outlook
The Eye Neoplasms market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Eye Neoplasms market trends by analyzing the impact of current Eye Neoplasms therapies on the market, Eye Neoplasms unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Eye Neoplasms market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Eye Neoplasms market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Eye Neoplasms market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Eye Neoplasms Market
-
Merck
-
Aura Pharmaceuticals
-
Novartis Pharmaceuticals
-
GlaxoSmithKline
-
Eilli Lilly
-
Bellicum Pharmaceuticals
And many others
Eye Neoplasms Therapies Covered and Analyzed in the Report:
-
Melatonin
-
Binimetinib
-
Lenvatinib
-
Capecitabine
-
Pembrolizumab
-
Doxycycline
And many others
Learn more about the Key Companies and Emerging Therapies in the Eye Neoplasms Market
Table of Contents
-
Key Insights
-
Eye Neoplasms Introduction
-
Executive Summary of Eye Neoplasms
-
Disease Background and Overview
-
Epidemiology and patient population
-
Eye Neoplasms Emerging Therapies
-
Eye Neoplasms Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Eye Neoplasms Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services